http://www.reportlinker.com/p0794929/Commercializing-Pancreatic-Cancer-Drugs-in-Cancer-The-Faster-Route-to-Consider-Your-Options-and-Position-of-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
This report will excel your competitive awareness and decrease your decision making time in managing pancreatic cancer drug development. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.
This report comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in pancreatic cancer. BioSeeker has applied its unique drug assessment methodology to stratify the pancreatic cancer drug pipeline and discern the level of competition in fine detail.
Major Findings from this report:
* The identified competitive landscape of pancreatic cancer drugs is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 37 different clusters. The latter has a competing ratio which is more than two times higher than the comparable average of the pancreatic cancer drugs in general.
* Nine out of every ten drug target strategies in Phase III and Phase II development are new to pancreatic cancer drugs.
* The greatest number of new target strategies are found in Phase II (37%) and Phase I (18%) development.
* Small molecules, Antibodies and Reformulated drugs are the dominating compound strategies of pancreatic cancer drugs, which represent almost 80% of the entire pipeline.
* Besides Reformulated drugs, it is Protein and Peptide based pancreatic cancer drugs that have the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies.
* The highest number of described drug target strategies of pancreatic cancer drugs belongs to Pfizer, Hoffmann-La Roche, Novartis and AstraZeneca.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any pancreatic cancer drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.
1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group's Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights'™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 19
4.2 List of Tables19
5 Introduction 27
5.1 The Scope of this Report 27
5.2 Definitions 30
5.3 Abbreviations 30
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 31
6.1 Drug Repositioning in Oncology 31
6.2 Introduction to Targets of Pancreatic Cancer Drugs 32
6.2.1 Carboxy-lyase Activity Targets 39
6.2.2 Catalytic Activity Targets 40
6.2.3 Cell Adhesion Molecule Activity Targets 51
6.2.4 Chaperone Activity Targets 59
6.2.5 Cofactor Binding Targets 60
6.2.6 Cysteine-type Peptidase Activity Targets 62
6.2.7 Cytokine Activity Targets 69
6.2.8 DNA Binding Targets 75
6.2.9 DNA Repair Protein Targets 77
6.2.10 DNA Topoisomerase Activity Targets 80
6.2.11 DNA-directed DNA Polymerase Activity Targets 85
6.2.12 Extracellular Ligand-gated Ion Channel Activity Targets 92
6.2.13 Extracellular Matrix Structural Constituent Targets 94
6.2.14 G-protein Coupled Receptor Activity Targets 98
6.2.15 Growth Factor Activity Targets 108
6.2.16 GTPase Activity Targets 114
6.2.17 Hormone Activity Targets 123
6.2.18 Hydrolase Activity Targets 124
6.2.19 Ion Channel Activity Targets 125
6.2.20 Kinase Activity Targets 126
6.2.21 Kinase Binding Targets 138
6.2.22 Kinase Regulator Activity Targets 139
6.2.23 Ligand-dependent Nuclear Receptor Activity Targets 143
6.2.24 Ligase Activity Targets 144
6.2.25 Lipase activity 150
6.2.26 Lipid kinase activity 151
6.2.27 Lipid Phosphatase Activity Targets 154
6.2.28 Molecular Function Unknown Targets 155
6.2.29 Motor Activity Targets 165
6.2.30 Oxidoreductase Activity Targets 167
6.2.31 Peptidase Activity Targets 173
6.2.32 Peptide Hormone Targets 183
6.2.33 Peroxidase Activity Targets 185
6.2.34 Protein Binding Targets 186
6.2.35 Protein Serine/Threonine Kinase Activity Targets 188
6.2.36 Protein Threonine/Tyrosine Kinase Activity Targets 213
6.2.37 Protein Tyrosine Phosphatase Activity Targets 218
6.2.38 Protein-tyrosine Kinase Activity Targets 226
6.2.39 Receptor Activity Targets 237
6.2.40 Receptor Binding Targets 255
6.2.41 Receptor Signaling Complex Scaffold Activity Targets 260
6.2.42 RNA Binding Targets 264
6.2.43 RNA-directed DNA Polymerase Activity Targets 265
6.2.44 Serine-type Peptidase Activity Targets 266
6.2.45 Structural Constituent of Cytoskeleton Targets 271
6.2.46 Structural Molecule Activity Targets 273
6.2.47 Transcription Factor Activity Targets 274
6.2.48 Transcription Regulator Activity Targets 292
6.2.49 Transferase Activity Targets 298
6.2.50 Translation Regulator Activity Targets 299
6.2.51 Transmembrane Receptor Activity Targets 301
6.2.52 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 304
6.2.53 Transporter Activity Targets 340
6.2.54 Unclassified Targets 345
6.2.55 Voltage-gated Ion Channel Activity Targets 346
6.2.56 Other Targets 347
Be the first to review this article
